Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Ethinyl estradiol
Drug ID BADD_D00844
Description Ethinylestradiol was first synthesized in 1938 by Hans Herloff Inhoffen and Walter Hohlweg at Schering.[A191107] It was developed in an effort to create an estrogen with greater oral bioavailability.[A191107] These properties were achieved by the substitution of an ethinyl group at carbon 17 of [estradiol].[A191107] Ethinylestradiol soon replaced [mestranol] in contraceptive pills.[A191107] Ethinylestradiol was granted FDA approval on 25 June 1943.[L11884]
Indications and Usage Ethinylestradiol is combined with other drugs for use as a contraceptive, premenstrual dysphoric disorder, moderate acne, moderate to severe vasomotor symptoms of menopause, prevention of postmenopausal osteoporosis.[L11944,L11965,L11947,L11950,L11845,L9806,L11953,L10304,L11956,L11959,L11962]
Marketing Status approved
ATC Code Not Available
DrugBank ID DB00977
KEGG ID D00554
MeSH ID D004997
PubChem ID 5991
TTD Drug ID D06NXY
NDC Product Code 63190-0620; 44132-010; 65089-0044; 12860-0463; 22552-0034; 44132-002; 60870-0463
UNII 423D2T571U
Synonyms Ethinyl Estradiol | Estradiol, Ethinyl | Ethynyl Estradiol | Estradiol, Ethynyl | Ethinyloestradiol | 19-Norpregna-1,3,5(10)-trien-20-yne-3,17-diol, (17alpha)- | Ethinyl Estradiol Hemihydrate | Hemihydrate, Ethinyl Estradiol | Ethinyl Estradiol, (8 alpha)-Isomer | Ethinyl Estradiol, (8 alpha,17 alpha)-Isomer | Ethinyl Estradiol, (8 alpha,9 beta,13 alpha,14 beta)-Isomer | Progynon C | Microfollin | Microfollin Forte | Ethinyl-Oestradiol Effik | Ethinyl Oestradiol Effik | Ethinylestradiol Jenapharm | Jenapharm, Ethinylestradiol | Lynoral | Estinyl | Ethinyl Estradiol, (9 beta,17 alpha)-Isomer
Chemical Information
Molecular Formula C20H24O2
CAS Registry Number 57-63-6
SMILES CC12CCC3C(C1CCC2(C#C)O)CCC4=C3C=CC(=C4)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Pulmonary embolism22.06.02.001; 24.01.06.001---
Pulmonary infarction22.06.02.002; 24.04.09.001---
Rash23.03.13.001---
Rash papular23.03.13.017---
Rash pruritic23.03.13.030---
Seizure17.12.03.001--
Skin discolouration23.03.03.005---
Skin hyperpigmentation23.05.01.003--
Skin irritation23.03.04.009---
Sleep disorder19.02.04.001---
Speech disorder17.02.08.003; 19.19.02.002; 22.12.03.027---
Stress19.06.02.004---
Swelling08.01.03.015---
Throat tightness19.01.02.005; 22.12.03.031---
Thrombophlebitis24.01.02.001---
Thrombosis24.01.01.006---
Thrombosis mesenteric vessel07.15.02.004; 24.01.08.001---
Unintended pregnancy18.08.01.001---
Urticaria10.01.06.001; 23.04.02.001--
Uterine haemorrhage21.07.01.005; 24.07.03.004--
Vaginal discharge21.08.02.002--
Vaginal haemorrhage21.08.01.001; 24.07.03.005--
Vaginal infection11.01.10.002; 21.14.02.002--
Venous thrombosis24.01.01.008---
Vision blurred06.02.06.007; 17.17.01.010--
Visual impairment06.02.10.013---
Vomiting07.01.07.003--
Vulvovaginal candidiasis11.03.03.005; 21.14.02.003---
Weight decreased13.15.01.005--
Weight increased13.15.01.006--
The 4th Page    First    Pre   4 5    Next   Last    Total 5 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene